Results 151 to 160 of about 81,917 (261)

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

OSBPL3 drives colorectal cancer progression via Hippo-YAP signaling and modulates MEK inhibitor sensitivity. [PDF]

Commun Biol
Zhong Y, Zheng C, Wang Z, Zhang W, Wu H, Luo J, Zhang H, Wang C, Zhang C, Hu H, Yuan Z, Wang M, Zhang Q, Wang G.   +13 more
europepmc   +1 more source

CD93—An emerging vascular target in cancer therapy

British Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira, Stefano Barbera, Roberta Lugano, Anna Dimberg   +3 more
wiley   +1 more source

Natural product‐derived TRPM7 channel inhibitors in neurological injury: Mechanisms, pharmacological potential and translational challenges

British Journal of Pharmacology, EarlyView.
Disruption of intracellular ionic homeostasis is a convergent pathological feature across diverse neurological injuries and disorders, including ischaemic and haemorrhagic stroke, hypoxic–ischaemic brain injury, traumatic brain injury, epilepsy and brain tumour.
Xinyang Zhang, Hio Lam Ho, F. David Horgen, Andrea Fleig, Zhong‐Ping Feng, Hong‐Shuo Sun   +5 more
wiley   +1 more source

Combination treatment with RAF/MEK inhibitor avutometinib and FAK inhibitor defactinib in preclinical models of meningioma. [PDF]

Neurooncol Adv
Ijad N, Waller KL, Yamazawa E, Nayyar N, Burgenske D, Torrini C, Carlson BL, Summers EJ, Migliarese C, Marion B, Zhang BS, Sullivan E, Ellington C, Sasisekharan V, Decker PA, Kosel M, Eckel-Passow JE, Galanis E, Sarkaria JN, Wakimoto H, Vaubel RA, Brastianos PK.   +21 more
europepmc   +1 more source

Interaction with NEGR1 affects mGlu5 cell signalling and the neuroprotection induced by the positive allosteric modulator VU0409551

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose The metabotropic glutamate receptor mGlu5 plays an important role in neuronal survival and synaptic plasticity. We and others have shown that mGlu5 positive allosteric modulators (PAMs) are biased agonists, triggering the activation of neuroprotective pathways and promoting neuronal survival. As mGlu5 biased pharmacology
Jennifer D. S. Guimaraes, Toniana G. Carvalho, Luan A. Pereira, Emanuele G. Silva, Esther M. A. Maciel, Gabriella P. Torres, Thiago Assis, Pablo L. Cardozo, Joao P. P. de Almeida, Nathalia C. Silva, Francesca Pischedda, Giovanni Piccoli, Luciene B. Vieira, Juliana Alves‐Silva, Fabiola M. Ribeiro   +14 more
wiley   +1 more source

Safety and Efficacy of MEK Inhibitor Treatment for Gastric Precancerous Lesions. [PDF]

Gastroenterology
Goldenring JR, Jang B, Gotoda T, Yamaguchi N, Choi E, Nomura S, Gastric Precancer Working Group.   +6 more
europepmc   +1 more source

Dietary melatonin and its benefits on cardiovascular disease

British Journal of Pharmacology, EarlyView.
Cardiovascular disease remains the leading cause of mortality globally, with a disproportionate burden in low‐ and middle‐income countries. Melatonin, a hormone primarily produced by the pineal gland, exhibits notable antioxidant, anti‐inflammatory and immunomodulatory properties that may confer cardiovascular benefits.
Karabo Tisane, Carmelita Abrahams, Sandrine Lecour   +2 more
wiley   +1 more source

Effects of combination therapy of a CDK4/6 and MEK inhibitor in diffuse midline glioma preclinical models. [PDF]

PLoS One
Tomita Y, Link G, Ge Y, Gold ERH, Racanelli A, Cardona HJ, Romero M, Gadd S, Watanabe J, Uchida E, Hashizume R, Takata N, Pinero G, Hambardzumyan D, Spasojevic I, Hu G, Hennika T, Brat DJ, Green AL, Becher OJ.   +19 more
europepmc   +1 more source

MEN1 Deficiency Drives Lung Cancer Progression via Activation of MMP10‐Mediated Angiogenesis

Cancer Science, EarlyView.
MEN1 deficiency promotes JunD‐mediated upregulation of MMP10 expression, which cleaves pro‐HB‐EGF and activates endothelial EGFR. This triggers the PI3K/Akt and MEK/ERK signaling pathways, thereby driving angiogenesis and tumor progression. MMP10 inhibitor treatment blocks this cleavage, suppresses EGFR signaling, and thereby delays malignant ...
Chengyu Wei, Xiangyu Liu, Shimin Hu, Xiaodie Shen, Yingli Liu, Xinxin Qin, Ye Zhou, Jianqi Zheng, Bingke Tian, Jingfang Hong, Yongxia Song, Di Wang, Linlin Peng, Jinxia Ding, Fang Wang, Hui Zhang, Shihao Zhang, Huan Qiu   +17 more
wiley   +1 more source